There is certainly concern that bipolar disorder, and especially bipolar II disorder, could be becoming overdiagnosed. There is proof for the utilization in acute bipolar depressive disorder of lamotrigine, lithium, olanzapine and quetiapine. Definite preventive results against bipolar unhappiness have already been demonstrated for lamotrigine, lithium, olanzapine and quetiapine . Although proof is conflicting concerning the efficacy of antidepressants in bipolar unhappiness and their inclination to induce mania or fast cycling, the authors consider they have got a valid role if they are found in conjunction with suitable preventive therapy . Cognitive behavioural therapy, psychoeducation and interpersonal and sociable rhythms have been been shown to be of worth in bipolar despair therapy..The Daily Health Plan Report is released for Kaisernetwork.org, a free of charge program of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Plank Kaiser and Company Family members Foundation. All rights reserved.
Biophor receives FDA 510 clearance for distribution of 7th oral fluid screening assay Biophor Diagnostics, Inc. This clearance completes the business's flagship panel for drugs of misuse screening in oral liquid. Oral liquid is a favored sample type since it is easy to get, hard to adulterate, and doesn’t have the privacy problems connected with urine samples. Biophor will leverage the globally accelerating development of oral liquid diagnostics in accordance with urine and other matrices to fully capture a significant part of the $2.8B worldwide medications of abuse testing marketplace.